Germ Cell Tumor of the Testis: Lethal Subtypes of a Curable Cancer

Author:

Jackson Jamaal C.1,Sanchez Darren1ORCID,Johns Andrew C.2,Campbell Matthew T.2ORCID,Aydin Ahmet M.3ORCID,Gokden Neriman4,Maraboyina Sanjay5,Muesse Jason L.6,Ward John F.1ORCID,Pisters Louis L.1,Zacharias Niki M.1,Guo Charles C.7,Tu Shi-Ming8

Affiliation:

1. Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

2. Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

3. Division of Urology, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA

4. Division of Pathology, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA

5. Division of Radiation Oncology, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA

6. Department of Surgery, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA

7. Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

8. Division of Hematology/Oncology, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA

Abstract

Germ cell tumor of the testis (GCT) is a curable cancer even when it is widely metastatic; however, outcomes can differ based on tumor histology. Chemo-resistance in certain phenotypes, such as teratoma and yolk sac tumor, contributes to poor clinical outcomes in some patients with GCT. Despite this resistance to S-YSTemic therapy, many of these tumor subtypes remain amenable to surgical resection and possible cure. In this study, we report on a series of seven patients highlighting two chemo-resistant subtypes of nonseminomatous germ cell tumor (NSGCT), sarcomatoid yolk sac tumor (S-YST), and epithelioid trophoblastic tumor (ETT) for which early resection rather than additional salvage chemotherapy or high-dose intense chemotherapy might provide a superior clinical outcome and enhance cure rate.

Funder

Harendra Mankodi

Jim B. Norton, M.D.

Publisher

MDPI AG

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3